Every 8-K that Madrigal Pharmaceuticals, Inc. (MDGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MDGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDGL filings page.
Madrigal Pharmaceuticals, Inc. expanded its Board of Directors from eight to nine members and elected John C. Reed, M.D., Ph.D. as a Class II director effective August 11, 2026, with a term expiring at the 2027 annual meeting. He was appointed to the Board’s Science and Technology Committee. As a non-employee director, he will receive an annual cash retainer of $50,000 plus $10,000 annually for committee service, under Madrigal’s Non-Employee Director Compensation Policy. In connection with his appointment, he will receive an equity grant valued at $675,000, split equally between nonqualified stock options and restricted stock units under the 2026 Stock Plan, subject to multi-year vesting tied to continued service. Madrigal highlighted Dr. Reed’s current leadership role at Johnson & Johnson and his extensive biopharmaceutical and research background, and reiterated its focus on Rezdiffra, the first medication approved by the FDA and European Commission for MASH with fibrosis stages F2 to F3.
Madrigal Pharmaceuticals reported second-quarter 2026 Rezdiffra net revenues of $364.3 million, up 71% from $212.8 million a year earlier, with more than 49,000 patients on therapy and nearly $1.3 billion in trailing-12-month net sales.
The company highlighted three new U.S. resmetirom patents expected to protect key uses into 2042–2045 and initiated first-in-human dosing for oral GLP-1 candidate MGL-2086 in a Phase 1 trial supporting combination MASH therapy. Operating expenses rose to $420.6 million, leading to a net loss of $57.9 million, while cash, cash equivalents, restricted cash and marketable securities totaled $838.9 million as of June 30, 2026.
Madrigal Pharmaceuticals used its latest annual meeting to update several compensation programs. On June 17, 2026, stockholders approved a new 2026 Stock Plan and a 2026 Employee Stock Purchase Plan, both previously adopted by the board and described in the company’s proxy statement.
The board also adopted a Nonqualified Deferred Compensation Plan, effective August 1, 2026, allowing selected executives and directors to defer portions of salary, bonuses, fees, and equity awards into notional investments tied to designated mutual fund options. The company may make discretionary contributions but does not currently intend to do so.
Separately, Madrigal entered a consulting agreement under which Dr. Rebecca Taub will transition from employee to consultant on July 1, 2026, providing scientific and medical guidance on MASH programs for an annual fee of $100,000, while continuing to receive the standard compensation paid to other non-employee directors.
Madrigal Pharmaceuticals reported strong first-quarter 2026 growth driven by its MASH drug Rezdiffra. Net revenues reached $311.3 million, up 127% from $137.3 million a year earlier, reflecting broad physician adoption and high patient demand.
Operating expenses rose to $404.1 million, including $54.3 million of one-time business development costs and $34.0 million of non-cash stock-based compensation. The company reported a net loss of $94.4 million, or $3.25 per share, compared with a $73.2 million loss in the prior-year quarter.
Madrigal ended March 31, 2026 with $817.9 million in cash, cash equivalents, restricted cash and marketable securities. More than 42,250 patients were on Rezdiffra as of March 31, 2026, and management highlighted that Rezdiffra has achieved blockbuster status on a trailing 12‑month net sales basis.
Madrigal Pharmaceuticals, Inc. reported a change in how its Board of Directors is classified, without changing who serves on the Board. On April 22, 2026, the Board rebalanced the membership of its three director classes so each class will be as evenly sized as possible after the 2026 Annual Meeting of Stockholders on June 17, 2026.
To accomplish this, Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, whose terms expire at the 2026 Annual Meeting. Each resigned from his prior Class III and Class II seat, respectively, solely to allow simultaneous reappointment as a Class I director, and their Board service is considered uninterrupted. Their committee assignments did not change, and both, along with James Daly, have been nominated for re-election at the 2026 Annual Meeting.
Madrigal Pharmaceuticals reported a breakout 2025, driven by its MASH drug Rezdiffra. Net revenues reached $321.1 million in the fourth quarter and $958.4 million for the full year, up sharply from $180.1 million a year earlier, with more than 36,250 patients on therapy by year-end.
Operating expenses also climbed, totaling $380.7 million in the quarter and $1,258.5 million for the year, reflecting heavy investment in commercialization and pipeline expansion. Madrigal ended 2025 with $988.6 million in cash and marketable securities and access to a senior secured credit facility of up to $500 million.
The company strengthened its long-term position with an Orange Book–listed Rezdiffra patent providing protection into 2045 and built an “industry-leading” MASH pipeline, including more than 10 programs such as siRNA candidates, an oral GLP-1 (MGL-2086), and the DGAT‑2 inhibitor ervogastat. Ongoing and planned trials aim to extend Rezdiffra’s use, including in compensated MASH cirrhosis (F4c).
Madrigal Pharmaceuticals amended its long-standing collaboration with Roche covering Rezdiffra. Effective January 29, 2026, Madrigal gains full and exclusive control over all patent term adjustments and patent term extensions applicable to Rezdiffra, including patents owned by Roche and those jointly owned.
In exchange for this expanded control of Rezdiffra’s patent life, the royalty that Madrigal pays Roche on net sales of Rezdiffra will not be reduced until certain patent term extensions that have been, or could have been, filed have expired. The amendment is documented in a First Amendment agreement filed as an exhibit.
Madrigal Pharmaceuticals (MDGL) reported that it furnished a press release announcing its financial results for the fiscal quarter ended September 30, 2025. The release is provided as Exhibit 99.1.
The information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Madrigal Pharmaceuticals held its 2025 Annual Meeting of Stockholders on June 20, 2025, with 20,427,421 shares represented (92% of outstanding shares), constituting a quorum. Key outcomes include:
- Board Elections: Four Class III directors were re-elected to serve until 2028, including Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse, and Dr. Richard Levy, with Dr. Fouse receiving the highest approval (18.8M votes)
- Auditor Appointment: Stockholders ratified PricewaterhouseCoopers LLP as independent auditor with overwhelming support (20.2M votes in favor)
- Executive Compensation: Shareholders approved named executive officers' compensation with strong support (18.7M votes in favor)
- Say-on-Pay Frequency: Stockholders strongly favored annual advisory votes on executive compensation (18.8M votes), which the Board has adopted